Published in Gastric Cancer on April 24, 2009
Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg (2010) 1.72
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer (2016) 1.61
Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol (2010) 1.44
Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today (2013) 1.02
Significance of lavage cytology in advanced gastric cancer patients. World J Surg (2010) 0.94
Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer (2013) 0.94
Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One (2014) 0.89
Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol (2015) 0.86
Oncologic outcomes of laparoscopic gastrectomy: a single-center safety and feasibility study. Surg Endosc (2013) 0.86
R0 resection in the treatment of gastric cancer: room for improvement. World J Gastroenterol (2010) 0.80
Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case. Surg Today (2012) 0.79
Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer (2014) 0.78
Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol (2015) 0.78
Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today (2017) 0.77
Improving outcome for scirrhous gastric cancer. Gastric Cancer (2009) 0.77
Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol (2015) 0.76
What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol (2014) 0.76
Evaluation of salvage surgery for type 4 gastric cancer. World J Gastrointest Surg (2012) 0.75
Impact of Combination Criteria of Nodal Counts and Sizes on Preoperative MDCT in Advanced Gastric Cancer. World J Surg (2016) 0.75
Japanese Classification of Gastric Carcinoma - 2nd English Edition - Gastric Cancer (1998) 16.63
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer (1998) 3.81
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology (2000) 3.50
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology (1999) 1.75
Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer. Gastric Cancer (2001) 0.84
Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Intern Med (1996) 0.82
Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study. Gastric Cancer (2003) 0.81
[Study on neoadjuvant chemotherapy of Borrmann 4 type carcinoma of stomach and its clinical significance]. Nihon Gan Chiryo Gakkai Shi (1990) 0.76
Scirrhous cancer of the stomach which survived for more than five years after neoadjuvant chemotherapy with UFT (uracil and tegafur) and cisplatin. Intern Med (2000) 0.76
Pilot study for preoperative administration of l-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother (1997) 0.75
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 9.00
Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer (2000) 8.85
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol (2010) 6.60
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol (2011) 6.53
Randomised trials in surgery: problems and possible solutions. BMJ (2002) 5.53
Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 5.17
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol (2011) 4.48
Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol (2004) 4.31
Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer (2009) 4.04
Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer (2006) 3.06
Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. Gastric Cancer (2011) 2.97
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol (2006) 2.73
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol (2008) 2.32
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol (2003) 2.27
Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg (2013) 2.19
Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer (2011) 2.18
Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol (2013) 2.16
Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer (2012) 2.09
High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg (2005) 2.04
Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol (2002) 2.03
Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification. Gastric Cancer (2002) 2.01
Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol (2008) 1.93
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res (2006) 1.90
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Relationship between epicardial fat measured by 64-multidetector computed tomography and coronary artery disease. Clin Cardiol (2011) 1.86
Focus on gastric cancer. Cancer Cell (2004) 1.82
Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer (2010) 1.81
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res (2012) 1.74
Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids. Bioorg Med Chem (2005) 1.71
Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol (2013) 1.66
Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol (2004) 1.63
Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial. Lancet Infect Dis (2012) 1.63
An assessment of the feasibility of sentinel lymph node-guided surgery for gastric cancer. Gastric Cancer (2004) 1.61
Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. Ann Surg (2014) 1.61
Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan. Gastrointest Endosc (2005) 1.60
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer (2011) 1.58
Improving outcomes after gastroesophageal cancer resection: can Japanese results be reproduced in Western centers? Arch Surg (2012) 1.55
Epstein-Barr virus infections of the central nervous system. Intern Med (2003) 1.55
Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer (2005) 1.53
Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int (2007) 1.50
Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol (2002) 1.46
How do the type and location of a vascular malformation influence growth in Klippel-Trénaunay syndrome? Plast Reconstr Surg (2011) 1.45
Preliminary experience with intraoperative near-infrared fluorescence imaging in percutaneous sclerotherapy of soft-tissue venous malformations. Dermatol Surg (2013) 1.44
Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol (2012) 1.38
Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery. Gastric Cancer (2011) 1.36
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol (2009) 1.34
Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer (2009) 1.33
Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol (2007) 1.33
Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol (2008) 1.31
Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg (2011) 1.28
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Surgical usefulness of indocyanine green as an alternative to India ink for endoscopic marking. Surg Endosc (2008) 1.28
Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg (2012) 1.28
A prospective feasibility and safety study of laparoscopy-assisted distal gastrectomy for clinical stage I gastric cancer initiated by surgeons with much experience of open gastrectomy and laparoscopic surgery. Gastric Cancer (2012) 1.26
Clinical diagnosis of metastatic gastric tumors: clinicopathologic findings and prognosis of nine patients in a single cancer center. World J Surg (2004) 1.26
Metastatic bone cancer as a recurrence of early gastric cancer -- characteristics and possible mechanisms. World J Gastroenterol (2005) 1.24
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci (2008) 1.23
A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer (JCOG0912). Jpn J Clin Oncol (2012) 1.20
Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg (2009) 1.20
Successful application of laparoscopic and endoscopic cooperative surgery (LECS) for a lateral-spreading mucosal gastric cancer. Gastric Cancer (2012) 1.20
Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol (2006) 1.19
Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol (2008) 1.19
Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol (2006) 1.18
Krüppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression. Int J Cancer (2009) 1.18
Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol (2013) 1.18